1. Peer review of the data = increased legitimacy of the science, the clinical development team, and the company as a whole 2. Publication in a high impact journal = greater exposure to the science and clinical pipeline 3. Thorough explanation of the materials & methods, and a review of specific patient outcomes = further insight into the potential success of the drug 4. P21 data! Enough said.